• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Novartis to Test Risk-Sharing Pricing Model for Heart Failure Drug Entresto

Article

The Swiss drug giant Novartis is looking at alternate pricing models for its heart failure drug Entresto, which is expected to gain FDA approval in August.

The Swiss drug giant Novartis is looking at alternate pricing models for its heart failure drug Entresto, which is expected to gain FDA approval in August.

Proven to improve heart function in individuals with a reduced ejection fraction, Entresto, also called LCZ696, will probably earn significant annual revenue for Novartis, projected in the billions. However, according to David Epstein, division head of Novartis, the company is working with healthcare systems to introduce a new outcomes-based payment model, where the initial discounted rate will be balanced by increased payments to Novartis if the drug reduces hospital visits.

The healthcare industry is gradually moving towards such clinical-outcomes—based risk-sharing models, and Novartis has already has a system in place for this for it's multiple sclerosis drug Gilenya.

Read more at Reuters:

http://reut.rs/1GKHoWz

Related Videos
Dr Guru Sonpavde
Video 2 - "Adverse Events & Existing Treatment Options for Dry Eye Disease"
Overview of Dry Eye Disease (DED) Causes and Treatments
Video 12 - "Harnessing Indication-Specific Data on Biosimilars"
Video 11 - "An Overview of Biosimilar Extrapolation During FDA Approval"
Video 3 - "Overview of BCG-Unresponsive Bladder Cancer Treatments Landscape"
Video 2 - "Bladder Cancer with FGFR Alterations: THOR-2 Cohort 1 Study at ESMO 2023"
Related Content
© 2023 MJH Life Sciences
AJMC®
All rights reserved.